# Cagrilintide Dosing Guide: Solo vs CagriSema 2.4 mg Weekly
> Note: PeptIQ is not a medical provider. Cagrilintide / CagriSema regulatory status can change by region. This is educational dosing literacy from public trial communications — not a prescription.
Cagrilintide is Novo Nordisk's long-acting amylin analogue. Most people meet it inside CagriSema — the once-weekly combination of cagrilintide with semaglutide — but "cagrilintide dosage" searches also want the monotherapy context.
Quick Answer: Cagrilintide Dosage
| Setting | Public dose anchor |
|---|---|
| CagriSema (REDEFINE obesity program) | Cagrilintide 2.4 mg + semaglutide 2.4 mg once weekly |
| Cagrilintide monotherapy arms (same program family) | Cagrilintide alone (commonly discussed at the 2.4 mg weekly level in Phase 3 comparison arms) |
| Semaglutide alone comparator | Semaglutide 2.4 mg weekly |
That 2.4 / 2.4 pairing is the SEO-stable number set — the same way "tirzepatide 15 mg" became a household phrase.
Why the Combo Dose Beat Either Alone
REDEFINE 1 public results (68 weeks, obesity/overweight without diabetes) showed the combination outperforming both monotherapies on mean weight loss. Approximate main-analysis style figures widely cited:
| Arm | Approx. mean weight change |
|---|---|
| CagriSema | ~−20% |
| Semaglutide alone | ~−15% |
| Cagrilintide alone | ~−11–12% |
| Placebo | ~−3% |
Adherence-estimating analyses pushed CagriSema even higher (low-20%s) with a large share of participants hitting ≥25% loss in public summaries.
Takeaway for dosing literacy: cagrilintide monotherapy is meaningful; pairing with GLP-1 is the headline product thesis.
Titration Reality (Not Instant 2.4 mg)
Obesity programs almost never start patients at the full maintenance combo on day one. Expect:
- Gradual escalation of one or both components
- GI monitoring at each step
- Holds for nausea/vomiting before forcing the schedule
- Long maintenance phase where 2.4 / 2.4 lives
If a future label differs, the label wins. Until then, "2.4 mg weekly amylin + 2.4 mg weekly GLP-1" is the correct public mental model for CagriSema.
Do Not Cross-Convert to Eloralintide Milligrams
| Drug | Public weekly anchors |
|---|---|
| Cagrilintide (CagriSema) | 2.4 mg |
| Eloralintide Phase 2 | 1–9 mg |
| Petrelintide Phase 2 | five weekly arms (mg table pending full release) |
Different molecules. Matching numbers is cargo-cult pharmacology.
